Hormonal control of the metabolic machinery of hepatocellular carcinoma by Wong, CCL et al.
Title Hormonal control of the metabolic machinery of hepatocellularcarcinoma
Author(s) Wong, CCL; Wong, CM; Ng, IOL
Citation Hepatobiliary Surgery and Nutrition, 2016, v. 5 n. 3, p. 195-197
Issued Date 2016
URL http://hdl.handle.net/10722/232159
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© HepatoBiliary Surgery and Nutrition. All rights reserved. HepatoBiliary Surg Nutr 2016;5(3):195-197hbsn.amegroups.com
Hepatocellular carcinoma (HCC) remains one of the most 
fatal malignancies worldwide. High death rate in HCC is 
mostly attributed to the lack of curative therapy and late 
symptom presentation. Only a minority of HCC patients 
are eligible for surgical resection or liver transplantation 
due to poor liver functions or presence of metastasis. 
Furthermore, HCC has a high recurrence rate and is 
highly resistant to conventional chemotherapies. So far, 
there is only one FDA-approved targeted therapy for 
advanced HCC patients, but its effect is only modest (1). 
Better knowledge regarding the molecular and metabolic 
alterations in HCC will be instrumental to the development 
of novel therapeutic interventions against HCC.
Warburg effect and hepatocellular  
carcinoma (HCC)
Liver is a center that coordinates the major metabolic 
events in our body. During the development of HCC, in 
the cancer cells, the normal hepatocytic functions are lost, 
accompanied by the acquisition of new metabolic traits 
that support the increased nutrient requirement for HCC 
cells. HCC cells prefer to metabolize glucose by glycolysis 
over oxidative phosphorylation to produce energy even in 
the presence of O2, a cancer hallmark which is also named 
the Warburg Effect (2). Although less energy efficient, this 
metabolic shift maximizes the production of anti-oxidants 
and building blocks for rapid cell division (3). In the August 
2015 issue of Hepatology, an elegant article by Nie et al. 
reports an important molecular pathway that contributes 
to the Warburg Effect in HCC (4). Nie et al. demonstrated 
that down-regulation of the mineralocorticoid receptor 
(MR) in HCC led to down-regulation of its transcriptional 
target, miR-338-3p, which resulted in the up-regulation 
of pyruvate kinase (PK) L/R and subsequently increased 
glycolysis (4). PK is a glycolytic enzyme which catalyzes 
the last step of glycolysis, transferring a phosphate group 
from ADP to phosphoenolpyruvate forming pyruvate 
and ATP. As pyruvate diverges into glycolysis and TCA 
cycle, PK determines the metabolic flux into glycolysis and 
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oxidative phosphorylation. PK has 4 isoforms which are 
derived from 2 genes, the PKL and PKM. The PKL gene 
produces the PKL and PKR isoforms, the transcriptions 
of which are initiated from two different tissue-specific 
promoters. The PKM gene produces PKM1 and PKM2 
by alternative splicing and resulting in a 9th and 10th exon-
containing PKM isoforms. PKL is highly expressed in liver 
and kidney. PKR is highly expressed in red blood cells. 
PKM1 is highly expressed in muscle, brain, and bladder. 
PKM2 is particularly abundant in cancer cells. PKM2, a less 
active isoform as compared to PKM1, favors tumor growth 
as PKM2 channels glucose intermediates from the TCA 
cycle to glycolysis (5,6). Most studies in the field compare 
the biochemical and oncogenic properties of PKM2 and 
PKM1 without taking into account of the PKL and PKR 
isoforms. Nie et al. beautifully showed that PKL/R isoforms 
enhanced the glycolytic flux of HCC cells and promoted the 
Warburg Effect (4). The deregulation of PKL is particularly 
important in the context of HCC and liver, as PKL is 
highly expressed in liver but not in other tissues. Of note, 
this study did not distinguish the roles of PKL and PKR. 
Our previous study showed that PKR expression was barely 
detectable in HCC and normal liver tissues (7), suggesting 
that effects observed by Nie et al. should be mediated 
mostly by PKL but not PKR. A long-standing question as 
to why cells of different tissue contexts express and require 
different PK isoforms is yet to be addressed. 
MiRNAs and pyruvate kinase (PK)
As PKL/R and PKM1/2 isoforms are derived from PKL 
and PKM genes, respectively, PKL/R and PKM1/2 share 
different 3’ untranslated regions (3’UTR). 3’UTR is 
recognized and bound by the miRNAs with complementary 
seed sequences, mediating degradation of the target 
mRNAs or translational repression (8). Therefore, PKL/R 
and PKM1/2 are regulated by different sets of microRNAs 
(miRNAs). Mounting evidence has documented those 
miRNAs that interfere with the 3’UTR of PKM1/2. MiR-
122, miR-let-7a, and miR-29b have been shown to directly 
interact and suppress PKM2 expression in various cancer 
models (7,9,10). PKM2 is known to be a transcriptional 
target of c-myc (11). MiR-290/371 cluster represses 
a transcriptional repressor of c-myc, Mdb2, thereby 
promoting c-myc-induced PKM2 expression and glycolysis 
in embryonic stem cells (11). While most studies tilt to 
reveal the miRNA regulation on PKM2, Nie et al. provides 
the first report to establish the link between miRNA and 
PKL/R (4). In HCC cells, Nie et al. showed that miR-338-
3p suppressed PKL/R and confirmed that miR-338-3p 
inhibited glycolytic flux (4). They also demonstrated that 
miR-338-3p and PKL/R expression levels were inversely 
correlated in human HCC samples (4). Intriguingly, they 
showed that miR-338-3p expression was controlled by a 
transcription factor, MR in human HCC (4).
Mineralocorticoid receptor (MR) system in liver
MR is also known as the aldosterone receptor as it is 
activated by its ligand, aldosterone, a steroid hormone 
produced by the adrenal gland. The MR-aldosterone 
system is particularly important to the kidney (12). Upon 
stimulation by aldosterone, MRs of the renal cells are 
translocated into the nucleus and bind to promoters of 
genes to activate their transcription to promote sodium 
and water retention and reduce potassium concentration in 
the blood, thereby increasing blood pressure. When blood 
flow in the kidney is decreased, renal cells produce renin 
which converts the angiotensinogen which is generated 
by the liver to angiotensin I and subsequently angiotensin 
II. Angiotensin II in turn stimulates renal cells to secrete 
aldosterone. The renin-angiotensin-aldosterone system 
is mainly regulated by the kidney and liver and plays an 
essential role in blood pressure maintenance. Increasing 
evidence has shown that MR expression is not restricted 
to renal cells but in different types of cells in the central 
nervous system, heart, blood vessels, sweat glands, brown 
adipose tissue, and colon (13). Nie et al. documented 
that MR could be detected in normal liver and was 
under-expressed in around 80% of HCC cases (4). This 
important clinical observation suggests that there may be 
some unknown functions of MR in the liver and HCC 
patients might have impairment in the renin-angiotensin-
aldosterone system.
Taken altogether, Nie et al. have beautifully disclosed 
that the loss of a component of a hormonal system, the 
MR, reprogrammed the metabolic machinery of HCC 
cells to aerobic glycolysis through the miR-338-3p-PKL/
R axis (4). In the coming future, in addition to drugs that 
directly target the metabolic enzymes in cancer cells, more 
translational efforts should be focused on the development 
of drugs that involve the activation of the MR-aldosterone 
system or other hormonal systems to target the Warburg 
Effect.
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